Skip to main content
. 2017 Jan 5;8(1):e210. doi: 10.1038/ctg.2016.63

Table 3. Associations between oxyntomodulin, glicentin, and vasoactive intestinal peptide and all glucoregulatory peptides.

Peptide model Oxyntomodulin
Glicentin
VIP
  β (95% CI) P value R2 β (95% CI) P value R2 β (95% CI) P value R2
Oxyntomodulin
 Unadjusted 0.24 (−0.05, 0.52) 0.103 0.032 0.01 (0.01, 0.02) <0.001 0.376
 Model 1 0.26 (−0.03, 0.54) 0.075 0.072 0.01 (0.01, 0.02) <0.001 0.385
 Model 2 0.24 (−0.03, 0.52) 0.083 0.132 0.01 (0.01, 0.03) <0.001 0.450
 Model 3 0.24 (−0.05, 0.52) 0.103 0.032 0.01 (0.01, 0.03) <0.001 0.428
Glicentin
 Unadjusted 0.14 (−0.03, 0.30) 0.111 0.032 0.00 (−0.01, 0.01) 0.405 0.009
 Model 1 0.15 (−0.02, 0.33) 0.087 0.044 0.00 (−0.01, 0.01) 0.425 0.025
 Model 2 0.15 (−0.02, 0.32) 0.083 0.103 0.00 (−0.01, 0.01) 0.460 0.128
 Model 3 0.14 (−0.03, 0.30) 0.101 0.060 0.00 (−0.01, 0.01) 0.420 0.096
Cholecystokinin
 Unadjusted 19.76 (13.02, 26.51) <0.001 0.306 8.96 (−2.31, 20.23) 0.119 0.033 0.31 (0.19, 0.43) <0.001 0.262
 Model 1 19.56 (12.90, 26.21) <0.001 0.308 8.81 (−2.34, 19.96) 0.121 0.076 0.31 (0.19, 0.43) <0.001 0.273
 Model 2 20.09 (13.48, 26.69) <0.001 0.338 7.97 (−2.88, 18.83) 0.150 0.133 0.32 (0.21, 0.42) <0.001 0.417
 Model 3 19.76 (13.02, 26.51) <0.001 0.306 8.96 (−2.31, 20.23) 0.119 0.033 0.30 (0.19, 0.41) <0.001 0.387
Ghrelin
 Unadjusted 0.13 (−0.16, 0.41) 0.381 0.009 0.31 (−0.06, 0.68) 0.105 0.032 0.00 (−0.02, 0.08) 0.199 0.020
 Model 1 0.13 (−0.16, 0.41) 0.379 0.017 0.34 (−0.03, 0.71) 0.069 0.072 0.03 (−0.02, 0.08) 0.189 0.027
 Model 2 0.14 (−0.16, 0.43) 0.359 0.077 0.24 (−0.13, 0.62) 0.199 0.121 0.04 (−0.01, 0.08) 0.130 0.155
 Model 3 0.13 (−0.16, 0.41) 0.381 0.009 0.31 (−0.06, 0.68) 0.105 0.032 0.01 (−0.01, 0.07) 0.261 0.104
VIP
 Unadjusted 35.61 (25.61, 45.61) <0.001 0.376 7.45 (−10.08, 24.98) 0.405 0.009
 Model 1 36.14 (26.29, 45.99) <0.001 0.387 7.12 (−10.38, 24.62) 0.425 0.045
 Model 2 38.34 (27.96, 48.71) <0.001 0.413 6.71 (−11.09, 24.52) 0.460 0.115
 Model 3 35.61 (25.61, 45.61) <0.001 0.376 7.45 (−10.08, 24.98) 0.405 0.009
GLP-1
 Unadjusted 0.01 (−0.16, 0.18) 0.915 0.000 0.10 (−0.13, 0.32) 0.402 0.009 0.00 (0.00, 0.01) 0.081 0.036
 Model 1 0.02 (−0.15, 0.19) 0.826 0.010 0.09 (−0.14, 0.31) 0.457 0.041 0.00 (0.00, 0.01) 0.099 0.040
 Model 2 0.05 (−0.15, 0.25) 0.610 0.071 0.03 (−0.23, 0.29) 0.826 0.104 0.03 (−0.01, 0.06) 0.051 0.185
 Model 3 0.01 (−0.16, 0.18) 0.915 0.000 0.10 (−0.13, 0.32) 0.402 0.009 0.02 (0.00, 0.05) 0.087 0.122
PYY
 Unadjusted 0.01 (−0.02, 0.03) 0.538 0.005 0.02 (−0.02, 0.05) 0.342 0.011 0.00 (−0.01, 0.01) 0.331 0.012
 Model 1 0.01 (−0.01, 0.04) 0.307 0.019 0.01 [−0.02, 0.05) 0.494 0.042 0.00 (−0.01, 0.01) 0.226 0.021
 Model 2 0.02 (−0.01, 0.04) 0.213 0.093 0.01 (−0.03, 0.04) 0.622 0.108 0.00 (0.00, 0.01) 0.240 0.143
 Model 3 0.01 (−0.02, 0.03) 0.538 0.005 0.02 (−0.02, 0.05) 0.342 0.011 0.00 (−0.01, 0.01) 0.366 0.100
Secretin
 Unadjusted 42.32 (28.44, 56.20) <0.001 0.301 32.94 (11.95, 53.93) 0.002 0.106 0.76 (0.51, 1.00) <0.001 0.313
 Model 1 45.25 (31.72, 58.76) <0.001 0.323 32.27 (11.30, 53.24) 0.003 0.130 0.78 (0.53, 1.01) <0.001 0.331
 Model 2 53.89 (39.76, 68.02) <0.001 0.376 29.76 (7.26, 52.27) 0.010 0.183 0.82 (0.58, 1.06) <0.001 0.447
 Model 3 42.32 (28.44, 56.20) <0.001 0.301 32.94 (11.95, 53.93) 0.002 0.106 0.82 (0.58, 1.07) <0.001 0.353

GLP-1, glucagon-like peptide-1; PYY, peptide YY; VIP, vasoactive intestinal peptide. All data are presented as β coefficient (95% CI); Model 1 for all glucoregulatory peptides was adjusted for age, sex, and ethnicity; Model 2 for all glucoregulatory peptides was adjusted for age, BMI, duration from first attack of AP, sex, ethnicity, etiology, recurrence, severity, smoking, and physical activity; Model 3 was adjusted for only those risk factors found to be significant in Model 2. Model 3 for glicentin and oxyntomodulin was adjusted for duration. Model 3 for oxyntomodulin and VIP was adjusted for etiology, and duration. Model 3 for oxyntomodulin and secretin was adjusted for etiology, ethnicity, recurrence, and duration. Model 3 for glicentin and VIP was adjusted for duration. Model 3 for glicentin and secretin was adjusted for etiology, recurrence, and duration. Model 3 for VIP and cholecystokinin was adjusted for etiology and duration. Model 3 for VIP and ghrelin, GLP-1, and PYY were adjusted for duration. Model 3 for VIP and secretin was adjusted for etiology. Significant (P<0.05) associations are shown in bold.